Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
NeoGenomics: Strong Revenue Growth and Strategic Initiatives Underpin Buy Rating Amidst Management Changes
Benchmark Co. Maintains NeoGenomics(NEO.US) With Hold Rating
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $19 to $19
Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
NeoGenomics Analyst Ratings
Craig-Hallum Sticks to Its Buy Rating for NeoGenomics (NEO)
Analysts' Top Healthcare Picks: ScPharmaceuticals (SCPH), NeoGenomics (NEO)
Benchmark Co. Downgrades NeoGenomics(NEO.US) to Hold Rating
NeoGenomics Cut to Hold From Buy by Benchmark
Raymond James Maintains NeoGenomics(NEO.US) With Hold Rating
Needham Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $19
NeoGenomics Analyst Ratings
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Craig-Hallum Releases a Buy Rating on NeoGenomics (NEO)
NeoGenomics Is Maintained at Neutral by B of A Securities
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $19
NeoGenomics Analyst Ratings
Jefferies Initiates NeoGenomics at Buy With $22 Price Target
Jefferies Initiates NeoGenomics(NEO.US) With Buy Rating, Announces Target Price $22